Author is bullish on Sellas Life Sciences (SLS), arguing the stock is rerating after the Regal trial update and that successful GPS results could drive multi-bagger upside.
SLS — LONG Author claims SLS is not a retail pump-and-dump and is rerating after the positive Regal study update, with the long-term opportunity intact. The stated catalyst is confirmation from the Regal trial, and the author sees extremely conservative price targets on successful GPS at 3-4x current levels, with personal fair value of 8-12 pre-readout and 4-5x after positive Regal results. The main stated risk is that the stock will see ups and downs as the market tries to price the opportunity prior to trial confirmation.
The risk STILL skews to the upside for me. Extremely conservative price targets on successful GPS are still 3-4x from where the stock is trading today.
This Reddit post, published January 07, 2026, features u/Interesting-Play-489 discussing SLS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Interesting-Play-489 · Tickers: SLS